Kinetics of Circulating Tumoral Cells in Bronchial Primitive Cancer

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03328559

Enrollment

Registered

2017-11-01

Start date

2016-03-07

Completion date

2021-08-20

Last updated

2021-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial Cancer

Brief summary

The pronostic value of Circulating Tumoral Cells(CTC) 's dosage by the method ISET® (tumoral cell isolation by size) in patients with bronchial cancer was previously demonstrated. However, no kinetic study was ever realized to study the value of the CTC as predictive indicator of answer to the therapy. This project plans to study patients in an early stage and patients at advance stage locally moved forward or metastatic of the disease by evaluation of the presence and the number of CTC before every cure. This collaborative and original study should allow to refine the diagnoses of answer and to plan the possible relapses what would allow a premature institution of the treatment.

Interventions

DIAGNOSTIC_TESTISET® - Isolation by Size of Tumor cells

early stage bronchial cancer patient will have a blood collection

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients with non-small cell lung cancer * accepting participation

Exclusion criteria

* refusing participation

Design outcomes

Primary

Measure	Time frame
numeration of CTC (circulant tumoral cell)	Day 1

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026